Grünenthal Partners with Clinect to Introduce Qutenza in Australia

Grünenthal's Strategic Move into the Australian Market

Grünenthal, a renowned name in pain management, has taken a significant step into the Australian pharmaceutical landscape. The company announced a strategic partnership with Clinect Pty Ltd, granting Clinect exclusive rights to market and distribute Qutenza® in Australia. This topical, non-opioid patch is specifically designed for the management of peripheral neuropathic pain, showcasing a commitment to innovative pain solutions without the risks associated with opioid medications.

Details of the Agreement

As part of this agreement, Clinect will handle all responsibilities related to obtaining marketing authorization for Qutenza in Australia. Following approval, they will initiate marketing and distribution efforts across the country. This collaboration is poised to enhance patient access to vital pain management resources, particularly for those suffering from conditions such as diabetes and postherpetic neuralgia.

Jan Adams, Chief Commercial Officer at Grünenthal, underscored the potential of Qutenza, expressing confidence in its effectiveness for those battling chronic pain. “We believe in the benefits this non-opioid treatment can provide and are eager to expand its availability worldwide,” he stated, highlighting the partnership's importance in penetrating the Australian market, a key area in the Asia-Pacific region.

A Commitment to Effective Pain Management

Merryn Wallace, the General Manager at Clinect, echoed Adams's sentiments, remarking on the shared dedication between the two companies towards improving patient outcomes. Wallace noted that this collaboration aligns seamlessly with Clinect’s strategy of working with innovators that introduce distinct therapies to the market. “We value the opportunity to introduce Qutenza to Australia,” she affirmed, emphasizing the shared goal of enhancing therapeutic options for patients.

Grünenthal’s commitment to this project is also evidenced by its recent history of acquisitions. Since acquiring the global rights to Qutenza in 2018, the firm has invested over €2.3 billion in strategic transactions, bolstering its portfolio and driving growth. This investment underlines their focus on diversifying product offerings while capitalizing on synergies within their operational framework.

What is Qutenza®?

Qutenza is an 8% capsaicin topical system that has received approval in various regions, including Europe and the United States. It is indicated for adults managing peripheral neuropathic pain, providing an effective option for individuals seeking relief without the adverse effects linked to opioids. In the U.S., Qutenza is recognized for its role in treating neuropathic pain associated with conditions like postherpetic neuralgia and diabetic peripheral neuropathy (DPN).

The patch works by delivering a high concentration of capsaicin, which targets pain receptors in the skin, resulting in a desensitizing effect that alleviates pain over time. Patients with chronic pain often face limitations in their daily lives, making access to effective treatments like Qutenza crucial.

The Bigger Picture

Grünenthal's headquarters in Aachen, Germany, and its operations across 28 countries showcase its international presence. With products available in around 100 nations, the company is well-positioned to leverage its global experience to enhance pain management solutions. The entry into the Australian market reflects their strategic vision for a world less burdened by pain, driven by innovation and patient-centric solutions.

By aligning with Clinect, Grünenthal is not only expanding its footprint but also reinforcing its mission to provide transformative healthcare solutions. The potential positive impact this partnership could have on Australian patients cannot be overstated, offering hope and relief through advanced medical treatments.

For further information about Grünenthal and Qutenza, visit their official website at Grünenthal.